A health food for promotion of quality of sleepy and metabolism, comprises the following components with a weight ratio of: 44.93 Milligrams ±25% of Magnesium (Mg), 3.8 Milligrams (±25%) of Zinc (Zn), 40 Micrograms (±25%) of Selenium (Se) and 40 Micrograms (±25%) of Chromium (Cr). Magnesium has the effect to promote ability of cardiovascular disease prevention; zinc can increase the power of mitochondria and enhance the power of metabolism, selenium serves to reduce risks of suffering from cancers and suppress the probability of infection of RNA virus, and Chromium has the effect of reduction of type 2 diabetes. A combination of above mentioned components has the overall effect of promotion of sleep quality, reduction of demand of sleep and increase abilities of diseases preventions.

A health food for promotion of quality of sleepy and metabolism, comprises the following components with a weight ratio of: 44.93 Milligrams ±25% of Magnesium (Mg), 3.8 Milligrams (±25%) of Zinc (Zn), 40 Micrograms (±25%) of Selenium (Se) and 40 Micrograms (±25%) of Chromium (Cr). Magnesium has the effect to promote ability of cardiovascular disease prevention; zinc can increase the power of mitochondria and enhance the power of metabolism, selenium serves to reduce risks of suffering from cancers and suppress the probability of infection of RNA virus, and Chromium has the effect of reduction of type 2 diabetes. A combination of above mentioned components has the overall effect of promotion of sleep quality, reduction of demand of sleep and increase abilities of diseases preventions.

This document provides methods and materials related to treating subjects having specific genetic variations associated with neurological disorders such as Parkinson's disease.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

The present disclosure pertains to a composition for treatment of glutaric aciduria and an administration method therefor and, specifically, to a pharmaceutical composition comprising recombinant human glutaryl-CoA dehydrogenase (rhGCDH) for treatment of glutaric aciduria and a method for treating glutaric aciduria, the method comprising a step of administering the pharmaceutical composition. Provided according to an aspect of the present disclosure are a pharmaceutical composition comprising recombinant human glutaryl-CoA dehydrogenase (rhGCDH) for treating glutaric aciduria and a novel method for treating glutaric aciduria through in vivo administration of the pharmaceutical composition (intravenously and subcutaneously; i.v. and s. c.), whereby an excellent effect is brought about through in vivo administration remarkably easier than intraventricular administration, with the expectation of more effectively regulating and treating glutaric aciduria.

The present disclosure pertains to a composition for treatment of glutaric aciduria and an administration method therefor and, specifically, to a pharmaceutical composition comprising recombinant human glutaryl-CoA dehydrogenase (rhGCDH) for treatment of glutaric aciduria and a method for treating glutaric aciduria, the method comprising a step of administering the pharmaceutical composition. Provided according to an aspect of the present disclosure are a pharmaceutical composition comprising recombinant human glutaryl-CoA dehydrogenase (rhGCDH) for treating glutaric aciduria and a novel method for treating glutaric aciduria through in vivo administration of the pharmaceutical composition (intravenously and subcutaneously; i.v. and s. c.), whereby an excellent effect is brought about through in vivo administration remarkably easier than intraventricular administration, with the expectation of more effectively regulating and treating glutaric aciduria.

This application relates to a composition and method for removing a hangover or improving liver function. The composition can show an excellent hangover removal effect, and thus can be effectively used in a food composition or health functional food composition for removing or ameliorating a hangover and improving liver function. The method may include administering an effective amount of a composition comprising an omega-3 fatty acid as an active ingredient to a subject in need thereof.

This application relates to a composition and method for removing a hangover or improving liver function. The composition can show an excellent hangover removal effect, and thus can be effectively used in a food composition or health functional food composition for removing or ameliorating a hangover and improving liver function. The method may include administering an effective amount of a composition comprising an omega-3 fatty acid as an active ingredient to a subject in need thereof.

Embodiments of a method and supplement for preventing and/or treating gastrointestinal distress, including ulcer conditions, in animals such as humans are disclosed. The supplement is in a tablet or capsule form and comprises mastic gum and an emulsifying agent such as lecithin. The supplement may also comprise B vitamins, one or more prebiotics or probiotics, and one or more minerals as well as, pH buffers and flavoring. A disclosed method of preventing and/or treating gastrointestinal distress comprises orally dosing an animal such as a human with the supplement at least once daily.